IMMP

Immutep Limited develops therapeutics designed to stimulate or suppress the immune system to combat cancer and autoimmune diseases. The company has a portfolio of immunotherapies, including four clinical stage candidates and one candidate at an early research stage. Its primary focus is on eftilagimod alfa (efti) for oncology and IMP761 for autoimmune diseases. Efti is a soluble LAG-3 protein that activates antigen-presenting cells, while IMP761 is a LAG-3 agonist antibody targeting activated T cells to address autoimmune disorders.